5-HT6 Ligand Indole Compounds for CNS Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the 5-HT6 receptor have limitations in efficacy and specificity for treating central nervous system disorders, hematological disorders, eating disorders, and other conditions, with a need for more effective therapeutic agents that modulate 5-HT6 receptor functions.
Innovation Solution
Development of novel 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds with high affinity for the 5-HT6 receptor, which are used in pharmaceutical compositions to treat various disorders, including CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds targeting 5-HT6 receptor are used, then some therapeutic effect is achieved, but efficacy and specificity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying key molecular parameters including the heterocyclyl ring structure (positions 2-7 of piperidine, morpholine, pyrrolidine), substituent types at different positions (R1-R6 groups), and alkyl chain lengths. These parameter modifications optimize the compounds' affinity for 5-HT6 receptors while maintaining selectivity, directly addressing the insufficient efficacy and specificity of existing compounds
Solution Approach 2:
The patent employs composite molecular structures combining indole core with heterocyclylalkyl side chains and arylsulfonyl groups. This composite approach creates molecules with multiple interaction points for the 5-HT6 receptor, enhancing both binding affinity and therapeutic efficacy compared to simpler existing compounds
2Reliability
If compound structure is optimized for higher 5-HT6 receptor affinity, then therapeutic benefit increases, but complexity of compound structure increases
Solution Approach 1:
The patent segments the molecular structure into distinct functional modules: an indole core, a heterocyclyl ring system (positions 2-7), variable substituent groups (R1-R6), and arylsulfonyl moieties. This segmentation allows independent optimization of each module's contribution to binding affinity while managing overall molecular complexity through systematic variation of discrete components
Solution Approach 2:
The patent creates a universal scaffold structure where the core indole-heterocyclyl framework can accommodate multiple different substituent patterns (R1-R6 groups) to target 5-HT6 receptor. This multi-functional design allows a single molecular architecture to achieve high affinity through various substituent combinations, reducing the need for entirely different molecular designs
Data Source
AI summary
The present invention relates to novel 5-(Heterocyclyl)alkyl-N- (arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.